Form 8-K - Current report:
SEC Accession No. 0000950170-24-123265
Filing Date
2024-11-07
Accepted
2024-11-07 16:05:10
Documents
16
Period of Report
2024-11-07
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K okur-20241107.htm   iXBRL 8-K 60038
2 EX-15.1 okur-ex15_1.htm EX-15.1 6031
3 EX-16.1 okur-ex16_1.htm EX-16.1 3705
4 EX-99.1 okur-ex99_1.htm EX-99.1 721402
5 EX-99.2 okur-ex99_2.htm EX-99.2 161521
6 EX-99.3 okur-ex99_3.htm EX-99.3 585704
  Complete submission text file 0000950170-24-123265.txt   1746999

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT okur-20241107.xsd EX-101.SCH 24879
18 EXTRACTED XBRL INSTANCE DOCUMENT okur-20241107_htm.xml XML 4720
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40315 | Film No.: 241435489
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)